- Your cart is empty
- Continue Shopping
Abamune 300mg
Abamune 300mg
Abacavir
Price range: $30.00 through $70.00
Tablets
Choose an option
✓ Discreet packaging
✓ 7–15 business days delivery
✓ Card, crypto & bank transfer
Add to cart
Buy Now
💊 Abamune 300 mg — pharmaceutical-grade abacavir by Cipla. Generic alternative to Ziagen® for HIV-1 infection.
📋 Product Overview
🧬 Active IngredientAbacavir Sulfate
💊 IndicationHIV-1 Infection (part of combination ART)
🇺🇸 US BrandZiagen®
🏭 ManufacturerCipla Ltd.
📦 Packaging30 tablets in HDPE bottle
💪 Strength300 mg
🚚 Delivery Time7–14 days (Worldwide)
⚙️ Introduction to Abamune
Abamune by Cipla contains Abacavir, a nucleoside reverse transcriptase inhibitor (NRTI) for HIV-1 treatment. It is a critical component of modern antiretroviral therapy (ART), often used in combination regimens like Abacavir + Lamivudine + Dolutegravir.
⚠️ Critical Safety Considerations:
- 🧬 Mandatory HLA-B*5701 screening before initiation (fatal hypersensitivity risk in positive patients)
- ❤️ Increased myocardial infarction risk in patients with cardiac risk factors
- ✅ Preferred for patients with renal impairment (no dose adjustment needed)
- ⚠️ Black-box warning for hypersensitivity reactions (fever, rash, multi-organ involvement)
Cipla’s 30-tablet bottle provides a month’s supply for combination regimens like Abacavir+Lamivudine+Dolutegravir.
💊 Dosage & Indications
| 💉 Indication | 🧪 Dosage | ⏱️ Frequency | 💡 Notes |
|---|---|---|---|
| Adults | 600 mg/day | Once daily or 300 mg BID | HLA-B*5701 negative only |
| Children ≥25kg | 300 mg BID | Twice daily | Oral solution for <25kg |
| Renal Impairment | No adjustment needed | – | Preferred over TDF |
| Hepatic Impairment | Avoid in severe cirrhosis | Contraindicated | Reduced metabolism |
⚠️ Side Effects, Storage & Warnings
❗ Common Side Effects
- Nausea (19%)
- Headache (13%)
- Fatigue (9%)
🚫 Life-Threatening Effects
- Hypersensitivity reaction (fever, rash, respiratory failure)
- Myocardial infarction (in high-risk patients)
- Lactic acidosis
❄️ Storage: 15–30°C; keep bottle tightly closed (desiccant included).
⚠️ Critical Warnings:
- Contraindicated without confirmed HLA-B*5701 negative status
- Discontinue permanently if hypersensitivity suspected
- Monitor cardiovascular risk factors biannually
🌍 Global Availability & Shipping
| 🌎 Region | 📦 Shipping | 💵 Price (30-tablet bottle) | 📜 Prescription |
|---|---|---|---|
| 🇺🇸 USA | ✅ Yes | $45–$80 | Required |
| 🇬🇧 UK | ✅ Yes | £35–£65 | Required |
| 🇦🇺 Australia | ✅ Yes | AUD 60–100 | Required |
🔗 Related Antiretroviral Alternatives
| 💊 Product Name | 🏭 Manufacturer | 🔗 Link |
|---|---|---|
| Tenvir (Tenofovir) | Cipla | View → |
| Lamivir (Lamivudine) | Cipla | Lamivir |
| Viraday (Efavirenz/FTC/TDF) | Cipla | View → |
| Taffic (Bictegravir/TAF/FTC) | Hetero | View → |
| Dolutranz (Dolutegravir/Tenofovir) | Mylan | Dolutranz |
| Abamune-L (Abacavir/Lamivudine) | Cipla | View → |
🩺 Hypersensitivity Reaction (HSR) Management Protocol
| Symptom Onset | Action |
|---|---|
| Within 6 weeks | Permanent discontinuation |
| Fever + Rash | ER visit immediately |
| Respiratory symptoms | Epinephrine + corticosteroids |
❤️ Cardiovascular Monitoring Protocol
| Parameter | Frequency | Action Threshold |
|---|---|---|
| Blood Pressure | Quarterly | >140/90 mmHg |
| Lipid Profile | Biannual | LDL >160 mg/dL |
| ECG | Baseline | Ischemic changes |
📦 Bottle Specifications
- Amber HDPE bottle with induction seal
- Tablet ID: “ABA300” engraving
- Hypersensitivity warning card included
⚠️ Drug Interactions
| Concomitant Drug | Risk | Action |
|---|---|---|
| Ethanol | ↑ Abacavir levels 40% | Avoid excessive alcohol |
| Methadone | No interaction | Safe for MAT patients |
| Ribavirin | ↑ Lactic acidosis risk | Avoid concurrent use |
🧬 HLA-B*5701 Screening Protocol
- Test before first prescription
- Document negative result in medical record
- Re-testing unnecessary if negative
📚 External Medical References
- WHO: Abacavir in HIV Treatment 2025
- FDA: Ziagen Black Box Warning
- DHHS: Hypersensitivity Reaction Management
🩺 Dr. Priya Desai, HIV Pharmacologist
“Abamune’s renal safety makes it ideal for older patients but demands strict HLA-B*5701 screening. For those with cardiovascular risks, Tenofovir is safer. Cipla’s bottle includes a hypersensitivity warning card – ensure patients carry it at all times.”
📺 Educational video: Understanding Abacavir therapy and hypersensitivity screening
⚠️ Disclaimer
This information is not medical advice. Use under physician supervision. Cipla’s Abamune carries black-box warnings for fatal hypersensitivity reactions. Mandatory HLA-B*5701 screening required before initiation. Discontinue permanently if hypersensitivity suspected.
🔐 Discreet Packaging • 💳 Multiple Payment Options • 📦 Guaranteed Reshipment • 🌍 Worldwide Shipping
Additional Information
| Active | Abacavir |
|---|---|
| Tablets | 30, 60, 90 |
Related products
